United Biologics, L.L.C. v. Amer Acdmy of A

CourtCourt of Appeals for the Fifth Circuit
DecidedJune 24, 2020
Docket19-50257
StatusUnpublished

This text of United Biologics, L.L.C. v. Amer Acdmy of A (United Biologics, L.L.C. v. Amer Acdmy of A) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fifth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United Biologics, L.L.C. v. Amer Acdmy of A, (5th Cir. 2020).

Opinion

Case: 19-50257 Document: 00515464789 Page: 1 Date Filed: 06/24/2020

IN THE UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT United States Court of Appeals Fifth Circuit

FILED June 24, 2020 No. 19-50257 Lyle W. Cayce Clerk UNITED BIOLOGICS, L.L.C., doing business as United Allergy Services; ACADEMY OF ALLERGY & ASTHMA IN PRIMARY CARE,

Plaintiffs - Appellants

v.

ALLERGY AND ASTHMA NETWORK/MOTHERS OF ASTHMATICS, INC.; TONYA WINDERS,

Defendants - Appellees

Appeal from the United States District Court for the Western District of Texas USDC No. 5:14-CV-35

Before STEWART, DENNIS, and HAYNES, Circuit Judges. PER CURIAM:* United Allergy Services 1 and Academy of Allergy & Asthma in Primary Care (“Academy”) (collectively, “Plaintiffs”) sued a number of defendants for Sherman Act and Texas antitrust violations, Texas common law tortious

* Pursuant to 5TH CIR. R. 47.5, the court has determined that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5TH CIR. R. 47.5.4. United Biologics LLC does business as United Allergy Services, and it was formerly 1

known as United Allergy Labs. We refer to this entity as United Allergy. Case: 19-50257 Document: 00515464789 Page: 2 Date Filed: 06/24/2020

No. 19-50257 interference with existing contracts and prospective business relations, and civil conspiracy to commit those torts. The district court entered a directed verdict for the two defendants who went to trial, Allergy and Asthma Network/Mothers of Asthmatics, Inc. (“Mothers”) and Tonya Winders (collectively, “Defendants”). United Allergy and Academy now appeal; we affirm.

I. Background United Allergy offers an alternative way to obtain allergy treatment. Under the traditional model, allergy sufferers seek treatment from a certified allergist who administers immunotherapy. Companies like Phadia US Inc. 2 sell equipment for allergy blood tests, which are often done in labs. United Allergy saw opportunity in the small number of allergists compared to allergy sufferers and began contracting directly with primary-care physicians for immunotherapy treatment. In exchange for a fee, United Allergy would provide technicians and assist physicians with immunotherapy equipment and supplies. To support its business, United Allergy helped form and fund Academy, a non-profit organization of physicians that “represent[s] the interests of . . . primary care physicians that provide allergy and asthma care to their patients.” Individual defendant Tonya Winders was first the market development team leader at Phadia and later the president and CEO of Mothers, a patient advocacy organization. While at Phadia, Winders identified United Allergy as a market obstacle to traditional allergy businesses. In one e-mail, a Phadia

2 Phadia is a former defendant in this case that settled before trial, which will become important below. References to Phadia may also refer to its parent company, Thermo Fisher Scientific Inc.

2 Case: 19-50257 Document: 00515464789 Page: 3 Date Filed: 06/24/2020

No. 19-50257 employee said that he, Winders, and another employee wanted to “compile a broad strategy to wipe these [companies] off the face of the earth.” By August 2011, Winders had formulated what she called “[her] plan for leading the charge to stop this market obstacle from negatively impacting [business] further.” Phadia trained its clinical sales consultants to provide information to physicians about remote allergy providers. In a regional meeting, it listed three talking points for sales consultants to use when interacting with customers: (1) patients are safer when receiving traditional allergy and asthma care, (2) board-certified allergists receive extensive training to become certified and prepared to address potential problems during treatment, and (3) the billing practices of remote allergy providers are concerning and could implicate providers if found to be illegal. In 2011, the Department of Health and Human Services’ Office of the Inspector General (“OIG”) issued an advisory opinion regarding a business model similar to United Allergy’s and concluded that it “could potentially generate prohibited remuneration under the anti-kickback statute.” 3 U.S. Dep’t of Health & Hum. Servs., Re: OIG Advisory Opinion No. 11-17, at 1 (Nov. 23, 2011). Phadia shared the opinion internally as something that would “help . . . combat these companies.” It also shared the opinion with a company that was negotiating with United Allergy, the Hospital Corporation of America. In an e-mail chain, a Phadia employee said that he may have “prevented a clinic

3 The opinion was requested by the owner of a company named Universal Allergy Labs—similar to United Allergy’s former name, United Allergy Labs—and which is now supposedly named Universal Allergy Services—similar to United Allergy Services. The purpose was ostensibly to gather information on implementing a business model similar to United Allergy’s. The requester sent the OIG a sample contract substantially the same as one of United Allergy’s form contracts. After Winders became its president, Mothers hired a consultant who had been involved with the request for the OIG opinion, although they both testified that the two events were unconnected.

3 Case: 19-50257 Document: 00515464789 Page: 4 Date Filed: 06/24/2020

No. 19-50257 from signing on with [United Allergy].” Phadia also distributed publications authored by Mothers, and on one occasion, an insurance provider Phadia had contacted told non-certified physicians to cease remote allergy treatments. Mothers also campaigned against remote allergy practice, including by distributing articles, in part under Winders’s direction. Beginning in 2013, United Allergy’s business declined; it lost insurance reimbursements and ultimately substantially diminished its business. Academy, for its part, lost many of its members. United Allergy and Academy filed the instant suit in 2014, later amending their complaint to add Mothers, Winders, and Phadia as defendants, which brought the number sued to more than a dozen. They alleged violations of Section 1 of the Sherman Act 4 and Texas law: namely, section 15.05(a) of the Texas Free Enterprise and Antitrust Act, 5 common law tortious interference with existing contracts and prospective business relations, and common law civil conspiracy. At the time of trial in 2016, all defendants except the appellees, Mothers and Winders, had settled. After trial, the Defendants moved for a directed verdict, arguing in part that civil conspiracy was a “legal impossibility” because Phadia, which allegedly committed the underlying tort, had settled. They urged that “[t]he Court [could not] adjudicate the conduct of parties who [were not] before it,” “there [was] no other way for the Court to adjudicate the underlying tort at issue,” and “Miss Winders [could not] conspire with her own company.” The district court agreed and entered a directed verdict on the issue of civil conspiracy. The jury then unanimously found that neither Mothers nor

4 15 U.S.C. § 1. 5 TEX. BUS. & COMM. CODE ANN. § 15.05(a).

4 Case: 19-50257 Document: 00515464789 Page: 5 Date Filed: 06/24/2020

No. 19-50257 Winders individually committed tortious interference. The jury was asked a conditional question; although the condition was not met, it answered the question, finding that the “Defendants’ agreement with one or more of Phadia [or other defendants] was only an attempt to persuade . . . lawmakers to take official government action,” thus falling within the Noerr–Pennington safe harbor. 6 The Plaintiffs then moved for judgment as a matter of law and for a new trial.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Fluorine On Call Ltd v. Fluorogas Limited
380 F.3d 849 (Fifth Circuit, 2004)
United Mine Workers v. Pennington
381 U.S. 657 (Supreme Court, 1965)
C.E. Services, Inc. v. Control Data Corporation
759 F.2d 1241 (Fifth Circuit, 1985)
Baty v. ProTech Insurance Agency
63 S.W.3d 841 (Court of Appeals of Texas, 2002)
John Paul Mitchell Systems v. Randalls Food Markets, Inc.
17 S.W.3d 721 (Court of Appeals of Texas, 2000)
Carroll v. Timmers Chevrolet, Inc.
592 S.W.2d 922 (Texas Supreme Court, 1979)
Wal-Mart Stores, Inc. v. Sturges
52 S.W.3d 711 (Texas Supreme Court, 2001)
Tilton v. Marshall
925 S.W.2d 672 (Texas Supreme Court, 1996)
Massey v. Armco Steel Co.
652 S.W.2d 932 (Texas Supreme Court, 1983)
ACS Investors, Inc. v. McLaughlin
943 S.W.2d 426 (Texas Supreme Court, 1997)
RRR Farms, Ltd. v. American Horse Protection Ass'n, Inc.
957 S.W.2d 121 (Court of Appeals of Texas, 1997)
Khan v. GBAK Properties, Inc.
371 S.W.3d 347 (Court of Appeals of Texas, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
United Biologics, L.L.C. v. Amer Acdmy of A, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-biologics-llc-v-amer-acdmy-of-a-ca5-2020.